BSE filing, NSE: FINOPB. Summary written from the filing by ALFA Finder's alert engine.
Fino Payments Bank Ltd: key numbers
- Share price
- ₹121.31
- Market cap
- ₹1,010 Cr
- Revenue (annual)
- ₹248.2 Cr
- Net profit (annual)
- ₹52.46 Cr
- P/E (TTM)
- -66.1×Sector 20.3×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fino Payments Bank Ltd
All →Fino Payments Bank Earnings Call Transcript: Key Takeaways
Management focused on transition to Small Finance Bank (SFB) while rebuilding B2B and UPI volumes. Profitability remains under pressure due to heavy investment in technology and people ahead of the license conversion.
Fino Payments Bank Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹333.6 Cr (down 17% YoY), EBITDA ₹35.1 Cr, PAT loss ₹(20.9) Cr. Net revenue margin rose 96 bps to 38.1%. Bank is progressing toward Small Finance Bank conversion.
Fino Payments Bank Results Update
Fino Payments Bank's press release reports Q2 FY27 revenue of Rs.333.6 Crore and a H1 net loss. Loan referral disbursals surged 286% year-on-year.
Fino Payments Bank Q2 FY27 Results: Net Loss of ₹20.9 Cr
Fino Payments Bank Ltd reported revenue from operations of ₹74.5 Cr (+24.0% YoY) and a net loss of ₹20.9 Cr for Q2 FY27.
- Key figure
- Net loss ₹20.9 Cr
Fino Payments Bank Other Announcement
Fino Payments Bank has received a revised ESG rating from Crisil ESG Ratings & Analytics Limited, moving from 54-Adequate to 59-Adequate.
Fino Payments Bank Board Meeting Date
Fino Payments Bank has scheduled a board meeting for October 29, 2026, to consider and approve financial results for the quarter and half-year ended September 30, 2026.
Other business update announcements
All →Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Rajshree Sugars & Chemicals Business Update
Rajshree Sugars reported October 2026 operational data for its three sugar units. Sugar sales were 17,849 MT, with no cane crushed during the month.
Ugar Sugar Works Business Update
Ugar Sugar Works has informed the exchanges that crushing for the 2026-27 season started at its Ugar Unit on 06 Nov 2026. Crushing will ramp up to full capacity over time.
Aarti Drugs Business Update
Aarti Drugs disclosed that the US FDA inspected its subsidiary Pinnacle Life Science's Baddi plant on 2-6 November 2026 and issued three Form 483 observations. The company states there is no financial or operational impact.
GSM Foils Business Update
GSM Foils Limited reported Net Sales of Rs. 14,63,47,636 for October 2026, with April-October cumulative sales of Rs. 1,59,69,98,607. The monthly sales update is filed under Regulation 30.
- Value
- ₹14.63 Cr
Runwal Enterprises Business Update
Runwal Enterprises adopted a fair disclosure code for unpublished price sensitive information under SEBI PIT Regulation 8. The code is hosted on the company website.